
Please try another search
Robert W. Baird analyst Eric Coldwell maintained a Hold rating on PRA Health Sciences (NASDAQ:PRAH) on Wednesday, setting a price target of $171, which is approximately 1.44% above the present share price of $168.57.
Coldwell expects PRA Health Sciences to post earnings per share (EPS) of $0.89 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in PRA Health Sciences, with an average price target of $171.67.
The analysts price targets range from a high of $175 to a low of $169.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $933.78 million and a net profit of $83.07 million. The company's market cap is $10.92 billion.
According to TipRanks.com, Robert W. Baird analyst Eric Coldwell is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 14.0% and a 63.11% success rate.
PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It operates through Clinical Research and Data Solutions segment. The Clinical Research segment serves biopharmaceutical clients and offers outsourced clinical research and clinical trial related services. The Data Solutions segment involves in data and analytics; technology solutions and real-world insights; and services primarily to the company's life science clients. The company was founded in 1976 and is headquartered in Raleigh, NC.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.